From 1.5% to 5.9%: Deloitte explores what's fueling Big Pharma's R&D IRR climb

From 1.5% to 5.9%: Deloitte explores what's fueling Big Pharma's R&D IRR climb

Pharma’s long winter of diminishing R&D returns may be thawing. Despite decades of increased spending yielding less bang for the buck, the industry is regaining ground. Deloitte’s closely watched annual analysis charted the slide, with average forecast IRR falling from just over 10% in Deloitte’s inaugural 2010 analysis to a trough of just 1.5% by 2019, a… The post From 1.5% to 5.9%: Deloitte digs into what’s fueling Big Pharma’s R&D IRR climb a…